ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 40.27
+0.78 (1.98%)
At close: Sep 25, 2026
ANG Lifesciences India Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 526 | 241 | 297 | 589 | 993 | 2,432 | |
Market Cap Growth | 12.14% | -18.93% | -49.60% | -40.72% | -59.17% | 446.85% |
Enterprise Value | 1,282 | 1,103 | 1,112 | 1,243 | 1,668 | 3,307 |
Last Close Price | 40.27 | 18.42 | 22.72 | 45.08 | 76.05 | 187.68 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | - | - | 6.03 |
PS Ratio | 0.63 | 0.26 | 0.32 | 0.40 | 0.45 | 0.69 |
PB Ratio | 0.99 | 0.46 | 0.46 | 0.77 | 1.15 | 2.90 |
P/TBV Ratio | 0.99 | 0.46 | 0.46 | 0.77 | 1.15 | 2.90 |
P/FCF Ratio | 4.97 | 2.27 | - | - | 6.23 | - |
P/OCF Ratio | 4.77 | 2.18 | - | - | 3.77 | 9.84 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.53 | 1.19 | 1.20 | 0.85 | 0.76 | 0.93 |
EV/EBITDA Ratio | - | 302.99 | - | 13.97 | 7.40 | 4.88 |
EV/EBIT Ratio | - | - | - | 90.16 | 12.39 | 5.35 |
EV/FCF Ratio | 12.10 | 10.42 | - | - | 10.47 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.50 | 1.50 | 1.30 | 0.96 | 0.82 | 0.92 |
Debt / EBITDA Ratio | - | 63.86 | - | 7.47 | 3.10 | 1.14 |
Debt / FCF Ratio | - | 7.50 | - | - | 4.44 | - |
Net Debt / Equity Ratio | 1.43 | 1.43 | 1.24 | 0.88 | 0.75 | 0.84 |
Net Debt / EBITDA Ratio | -37.16 | 207.60 | -54.67 | 7.54 | 2.87 | 1.04 |
Net Debt / FCF Ratio | - | 7.14 | -19.86 | -4.45 | 4.05 | -4.23 |
Asset Turnover | - | 0.42 | 0.39 | 0.56 | 0.77 | 1.63 |
Inventory Turnover | - | 1.24 | 1.17 | 1.98 | 3.53 | 8.11 |
Quick Ratio | - | 0.49 | 0.50 | 0.55 | 0.56 | 0.66 |
Current Ratio | - | 1.00 | 1.15 | 1.24 | 1.14 | 1.16 |
Return on Equity (ROE) | - | -18.97% | -17.70% | -12.48% | -0.31% | 64.33% |
Return on Assets (ROA) | - | -1.45% | -1.81% | 0.33% | 2.96% | 17.79% |
Return on Invested Capital (ROIC) | -5.94% | -3.74% | -4.77% | 0.94% | -0.88% | 39.67% |
Return on Capital Employed (ROCE) | - | -8.50% | -7.90% | 1.40% | 11.70% | 49.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -25.34% | -46.09% | -41.84% | -17.23% | -0.26% | 16.58% |
FCF Yield | 20.14% | 44.03% | -13.51% | -25.59% | 16.04% | -6.84% |
Dividend Yield | - | - | - | - | - | 0.43% |
Payout Ratio | - | - | - | - | - | 2.57% |
Buyback Yield / Dilution | 1.32% | - | - | -0.51% | -0.26% | - |
Total Shareholder Return | 1.32% | - | - | -0.51% | -0.26% | 0.43% |